Efgartigimod is the first and only treatment for patients with generalized myasthenia gravis (gMG). gMG is a debilitating disease that happens in the neuromuscular junction (NMJ). This is a uniquely engineered drug that is the Fc portion of an antibody—the fragment. For our Recharge campaign, we are visually representing the mechanism of action—activation—happening on the NMJ through this beautiful cityscape coming out from the fragment. This campaign took us a year from concept to final product by working with amazing professionals in the medical industry through multiple research and testing, both globally and in the US.